Skip to main content

Table 4 All-cause ESKD-associated variants at P < 5 × 10–6 in baseline model

From: Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

Lead variant CHR POS Locus Effect/other alleles Info Stage 2 (3432 T2D-ESKD cases vs. 6977 non-diabetic non-nephropathy controls) Stage 4 (1910 non-diabetic ESKD cases vs. 908 non-diabetic non-nephropathy controls) Stage 5: Meta-analysis (5342 all-cause ESKD cases vs. 6977 non-diabetic non-nephropathy controls)
EAF OR (95% CI) P EAF OR (95% CI) P EAF OR (95% CI) P HetP
rs76971802 3 188607071 LPP T/C 0.95 0.087 1.35 (1.19,1.54) 8.66E−06 0.084 1.42 (1.08,1.87) 0.013 0.087 1.35 (1.2,1.52) 1.36E−06 0.86
rs5863506 4 162909217 FSTL5 TA/T 0.96 0.33 1.22 (1.12,1.32) 1.64E−06 0.33 1.19 (1.01,1.40) 0.033 0.33 1.21 (1.12,1.30) 4.57E−07 0.87
rs141746998 8 54310938 OPRK1/ATP6V1H CAT/C 0.94 0.031 0.62 (0.5,0.76) 9.40E−06 0.034 0.61 (0.39,0.93) 0.022 0.031 0.61 (0.5,0.75) 1.44E−06 0.96
rs11997465 8 110891977 SYBU/KCNV1 C/G 0.99 0.28 1.22 (1.12,1.33) 3.21E−06 0.28 1.21 (1.02,1.43) 0.026 0.28 1.22 (1.13,1.31) 6.72E−07 0.65
rs77113398 13 107103906 EFNB2 A/G 0.93 0.023 1.94 (1.52,2.47) 1.25E−07 0.021 1.87 (1.08,3.24) 0.025 0.023 1.94 (1.55,2.43) 9.84E−09 0.96
rs9622363 22 36656555 APOL1 A/G 0.95 0.45 0.77 (0.72,0.84) 1.42E−10 0.35 0.42 (0.36,0.48) 4.32E−29 0.43 0.68 (0.64,0.73) 1.96E−25 1.14E−09
  1. Baseline model: adjusted for age, sex, and PC1; APOL1 risk genotype carriers were included
  2. Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, CHR chromosome, POS position, EAF effect allele frequency, OR odds ratio, CI confidence interval, P, P value, Info average imputation quality, HetP heterogeneity P value